Brief: Clover And Ascentage Pharma Announce Clinical Collaboration

Ascentage Pharma International

09/12/2021 13:09

Dec 9 (Reuters) - Clover Biopharmaceuticals Ltd  2197.HK :
    * CLOVER AND ASCENTAGE PHARMA ANNOUNCE CLINICAL
COLLABORATION TO
EVALUATE RECOMBINANT HUMAN TRAIL-TRIMER FUSION PROTEIN, SCB-313,
IN COMBINATION WITH IAP ANTAGONIST, APG-1387 FOR THE TREATMENT
OF PERITONEAL CARCINOMATOSIS
    * ASCENTAGE PHARMA GROUP - WILL JOINTLY CONDUCT PHASE 1B/2
STUDY
TO EVALUATE SAFETY, TOLERABILITY, PK/PD, EFFICACY OF SCB-313
WITH APG-1387 WITH CLOVER

Source text for Eikon:  ID:nGNX3S1lJW 
Further company coverage:  2197.HK 

 ((Reuters.Briefs@thomsonreuters.com;))